Current emerging and investigational drugs for the treatment of chronic hand eczema

Introduction Chronic hand eczema (CHE) is a highly prevalent, burdensome condition associated with functional impairment. Currently, topical therapeutics are the mainstay of CHE management. However, many cases are refractory to existing topical therapeutics, and the few existing systemic options are often limited in efficacy and by their side effect profiles. Areas covered Following a brief overview of CHE pathogenesis and existing treatments, this review will outline the mechanisms and available data on emerging and investigational drugs currently being studied in clinical trials for the treatment of CHE. Expert opinion Immunomodulatory drugs such as topical and systemic JAK inhibitors and Th2-targeting antibodies such as dupilumab are currently under investigation for CHE treatment, with early promise. Management of CHE will likely move toward more targeted treatments through clinical trials and away from broad immunosuppressants such as cyclosporine and methotrexate, which have previously been investigated for CHE and have more side effects. In coming years, CHE patients may benefit from a wider range of both topical and systemic therapeutics that target immune pathways relevant to the various CHE subtypes.

Automated summary

Chronic hand eczema (CHE) is a burdensome condition with limited treatment options. This review discusses the pathogenesis and currently available treatments for CHE, as well as emerging drugs being studied in clinical trials. Expert opinion suggests that immunomodulatory drugs such as JAK inhibitors and Th2-targeting antibodies hold promise for CHE treatment. Future management of CHE may involve more targeted therapies through clinical trials, moving away from broad immunosuppressants with more side effects.